INDEX OF FIGURESFigure 2.1: Geographic Distribution of Tissue Engineering Firms in Major Markets 32Figure 2.2: The Potential Uses of Embryonic Stem Cells 33Figure 2.3: Progress of Cell Therapy Product Research, 2012 34Figure 2.4: Commercially Available Cell Therapy Products, 2012 35Figure 2.5: Disease Focus by Regenerative Medicine 39Figure 2.6: Estimated Completion Dates for Stem Cell Based Clinical Trials Targeting Type 1 Diabetes, 2009-2015 45Figure 2.7: Number of Clinical Trials by Targeted Condition, 2005-2011 45Figure 2.8: Concentration of European Cell Therapy Firms, 2012 46Figure 2.9: European Stem Cell Platforms by Cell Source 47Figure 2.10: Autologous vs. Allogeneic Stem Cell Therapy Firms in Europe, 2012 48Figure 2.11: Autologous and Allogeneic Somatic Cell Therapy Firms in Europe, 2012 48Figure 2.12: Sponsors of Cell Therapy Clinical Trials in the U.K., 2012 52Figure 2.13: Clinical Trials Involving Allogeneic vs. Autologous Cell Therapy Products in the U.K., 2012 52Figure 2.14: Cell Types Involved in the U.K. Cell Therapy Clinical Trials, 2012 53Figure 2.15: U.K. Cell Therapy Clinical Trials by Indication, 2012 54Figure 2.16: Cell Culture Products Market by Segment, 2012 55Figure 2.17: Market for Reagents Used in Cell Culture, 2012-2019 56Figure 2.18: Market for Media Used in Cell Culture, 2012-2019 57Figure 2.19: Market for Serum Used in Cell Culture, 2012-2019 58Figure 5.1: CIRM's Grants for Disease Types by Funding Level, 2012 110Figure 7.1: Commercially Available Regenerative Products 119Figure 7.2: Global Market for Tissue Engineering Products, 2012-2019 123Figure 7.3: Global RM Market for Cardiology and Vascular Products, 2012-2019 126Figure 7.4: Alternatives for Medtronic's Infuse 128Figure 7.5: Global Market for RM Products in Orthopedics, Musculoskeletal and Spine, 2012-2019 130Figure 7.6: Global RM Market for Neurology Products, 2012-2019 131Figure 7.7: Global RM Market for Dental Products, 2012-2019 132Figure 7.8: Global Tissue Engineering and Cell Therapy Market for Cancer Products, 2012-2019 133Figure 7.9: Global Market for RM Products in Urology, 2012-2019 134Figure 7.10: Global Market for RM Products in Skin/Integument, 2012-2019 135Figure 7.11: Global Tissue Engineering and Cell Therapy Market, 2012-2019 136Figure 7.12: U.S. Market for Tissue Engineered Skin Replacement and Substitutes, 2012-2019 137Figure 7.13: U.S. Market for RM Products in Orthopedic/Spine, 2012-2020 139Figure 7.14: U.S. Market for RM Products in Nerve Repair, 2012-2020 140Figure 7.15: U.S. Market for RM Products in Cardiovascular Therapies, 2012-2020 141Figure 7.16: U.S. Market for RM Products in Anti-Inflammatory Therapies, 2012-2020 142Figure 7.17: U.S. Market for RM Products in Diabetes, 2012-2020 143Figure 7.18: U.S. Market for Regenerative Medicines, 2012-2020 144Figure 7.19: U.S. Regenerative Medicine Market by Segment, 2020 145Figure 8.1: Global Market for Stem Cell Products, 2012-2020 148Figure 8.2: U.S. Market for Stem Cell Products, 2012-2020 151Figure 8.3: Estimated U.S. Market for Stem Cell Therapy by Type, 2020 153Figure 8.4: European Market for Stem Cell Products, 2012-2020 153Figure 8.5: Number of Autologous and Allogeneic Cell Therapy Firms in Europe 154Figure 8.6: Asia-Pacific Market for Stem Cells, 2012-2019 155Figure 8.7: Global Autologous Cell Therapy Market, 2012-2019 156Figure 9.1: Cell-Based Business Models 159Figure 9.2: Current Autologous Business Models 161Figure 9.3: Current Allogeneic Business Models 162Figure 10.1: Aastrom's Cell Expansion Process 167
Regenerative Medicine Markets
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.